Bristol pravastatin/aspirin co-package
Executive Summary
Bristol-Myers Squibb's NDA (21-387) for a pravastatin/aspirin co-package (tentatively named Pravaguard) will return to FDA's Cardiovascular & Renal Drugs Advisory Committee for consideration on the afternoon of July 18. The NDA was resubmitted following a Jan. 18 meeting at which the committee voted against approval for long-term management to reduce the risk of cardiovascular events in patients with clinically evident coronary heart disease (1"The Pink Sheet" Jan. 21, p. 7)...
You may also be interested in...
Pravachol/Aspirin Fixed-Dose Inflexibility May Lead To Undertreatment
Bristol-Myers Squibb's Pravachol/Bufferin titration inflexibility was cited as a main issue by FDA's Cardiovascular & Renal Drugs Advisory Committee in voting against approval of the fixed-dose combination of the cholesterol-lowering and aspirin products
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.